Astrazeneca PLC (NYSE:AZN) Stock Rating Lowered by BidaskClub
Astrazeneca PLC (NYSE:AZN) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Friday.
Several other equities analysts also recently issued reports on the stock. Barclays PLC reissued an “overweight” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Pareto Securities raised shares of Astrazeneca PLC from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Morgan Stanley downgraded shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, July 28th. Goldman Sachs Group, Inc. (The) reissued a “sell” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Finally, Leerink Swann downgraded shares of Astrazeneca PLC from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $36.00 to $31.00 in a report on Thursday, July 27th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company. Astrazeneca PLC has a consensus rating of “Hold” and an average target price of $33.39.
Shares of Astrazeneca PLC (NYSE AZN) traded down 0.56% during trading on Friday, reaching $30.17. 5,189,646 shares of the company’s stock were exchanged. Astrazeneca PLC has a 52 week low of $25.55 and a 52 week high of $35.60. The stock has a market capitalization of $76.39 billion, a PE ratio of 19.79 and a beta of 0.74. The company’s 50-day moving average is $33.57 and its 200 day moving average is $31.37.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.46. The firm had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The firm’s revenue was down 9.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.83 earnings per share. On average, analysts forecast that Astrazeneca PLC will post $1.85 earnings per share for the current year.
Large investors have recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Astrazeneca PLC during the fourth quarter valued at approximately $8,217,000. Teachers Advisors LLC boosted its stake in shares of Astrazeneca PLC by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 787,179 shares of the company’s stock valued at $21,506,000 after buying an additional 30,104 shares during the period. Macquarie Group Ltd. boosted its stake in shares of Astrazeneca PLC by 13.1% in the fourth quarter. Macquarie Group Ltd. now owns 485,066 shares of the company’s stock valued at $13,252,000 after buying an additional 56,100 shares during the period. CENTRAL TRUST Co boosted its stake in shares of Astrazeneca PLC by 2.1% in the first quarter. CENTRAL TRUST Co now owns 4,499 shares of the company’s stock valued at $140,000 after buying an additional 91 shares during the period. Finally, Fulton Bank N.A. boosted its stake in shares of Astrazeneca PLC by 44.5% in the first quarter. Fulton Bank N.A. now owns 37,404 shares of the company’s stock valued at $1,164,000 after buying an additional 11,520 shares during the period. Hedge funds and other institutional investors own 14.39% of the company’s stock.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.